Calcimimetic Compounds Modulating Calcium-Sensing Receptors for Bowel Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory bowel disorders (IBD) and irritable bowel syndrome (IBS) are inadequate, with many patients failing to respond to existing therapies and requiring surgery, and there is a need for more effective methods to manage chronic inflammation and symptoms.
Innovation Solution
The use of calcimimetic compounds that bind to calcium-sensing receptors, inducing a conformational change to reduce the threshold for receptor activation, thereby modulating calcium levels and reducing inflammation in the gastrointestinal tract, is proposed for treating IBD and IBS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for IBD and IBS are used, then some symptom relief may be achieved, but many patients fail to respond and require surgery
Solution Approach 1:
The patent applies parameter changes by modifying the calcium-sensing receptor's activation threshold through calcimimetic compounds. These compounds bind to the receptor and induce conformational changes that reduce the calcium concentration required for receptor activation, thereby enhancing the receptor's sensitivity and downstream anti-inflammatory signaling without requiring surgical intervention.
Solution Approach 2:
The calcium-sensing receptor acts as an intermediary molecule that mediates the effect of calcimimetic compounds on inflammatory pathways. By binding to this receptor, the compounds transmit their therapeutic effect through the receptor's signaling cascade, ultimately reducing inflammation in IBD and IBS conditions.
2Duration of action of stationary object
If existing therapies are continued for chronic IBD management, then some disease control is maintained, but 20-40% of patients eventually require surgery
Solution Approach 1:
The patent employs preliminary action by activating the calcium-sensing receptor before severe inflammation and surgical indications develop. The calcimimetic compounds preemptively enhance receptor signaling to prevent the progression to surgical-stage disease, thereby extending the duration of medical management and avoiding surgery in high-risk patients.
3Ease of operation
If standard IBD treatments are used, then some patients achieve symptom control, but treatment response varies widely and many fail therapy
Solution Approach 1:
The calcium-sensing receptor serves as a universal target for treating multiple bowel disorders including IBD and IBS. The calcimimetic compounds act on this common receptor pathway regardless of the specific disease subtype, providing a unified therapeutic mechanism that addresses diverse clinical presentations with a single agent class.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The calcimimetic compounds demonstrate therapeutic effectiveness by reducing inflammation, altering bowel habits, and improving symptoms in animal models of IBD, suggesting potential for improved treatment outcomes for patients with IBD and IBS.
Implementation Method 1
bind to calcium-sensing receptors, inducing a conformational change to reduce the threshold for receptor activation
Implementation Method 2
modulating calcium levels and reducing inflammation in the gastrointestinal tract
Data Source
Figure 1A~1D
Figure 2A~2B
Figure 3A~3D
AI summary
The present invention relates to methods for treating or preventing bowel disorders using calcimimetics.